stoxline Quote Chart Rank Option Currency Glossary
  
Aquestive Therapeutics, Inc. (AQST)
2.695  -0.035 (-1.28%)    06-18 11:37
Open: 2.76
High: 2.78
Volume: 250,886
  
Pre. Close: 2.73
Low: 2.67
Market Cap: 245(M)
Technical analysis
2024-06-18 11:18:16 AM
Short term     
Mid term     
Targets 6-month :  3.55 1-year :  3.88
Resists First :  3.03 Second :  3.32
Pivot price 2.83
Supports First :  2.56 Second :  2.13
MAs MA(5) :  2.74 MA(20) :  2.9
MA(100) :  3.54 MA(250) :  2.51
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  24.4 D(3) :  26.4
RSI RSI(14): 33.9
52-week High :  6.23 Low :  1.25
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AQST ] has closed above bottom band by 18.5%. Bollinger Bands are 64.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.76 - 2.77 2.77 - 2.79
Low: 2.55 - 2.57 2.57 - 2.59
Close: 2.7 - 2.73 2.73 - 2.76
Company Description

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

Headline News

Tue, 18 Jun 2024
Aquestive Therapeutics to join Russell 3000 and Russell 2000 indexes - Seeking Alpha

Tue, 18 Jun 2024
Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024 - StockTitan

Fri, 14 Jun 2024
All You Need to Know About Aquestive Therapeutics (AQST) Rating Upgrade to Buy - AOL

Thu, 09 May 2024
Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Just Came Out: Here's What Analysts Are ... - Yahoo Finance

Wed, 08 May 2024
Aquestive Therapeutics, Inc. (AQST) Q1 2024 Earnings Call Transcript - Seeking Alpha

Tue, 07 May 2024
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 91 (M)
Shares Float 80 (M)
Held by Insiders 4.9 (%)
Held by Institutions 46.2 (%)
Shares Short 6,180 (K)
Shares Short P.Month 4,010 (K)
Stock Financials
EPS -0.45
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.41
Profit Margin -55.9 %
Operating Margin -74.4 %
Return on Assets (ttm) -12.8 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 8.3 %
Gross Profit (p.s.) 0
Sales Per Share 0.56
EBITDA (p.s.) -0.2
Qtrly Earnings Growth 0 %
Operating Cash Flow -26 (M)
Levered Free Cash Flow -16 (M)
Stock Valuations
PE Ratio -6.01
PEG Ratio 0
Price to Book value -6.75
Price to Sales 4.77
Price to Cash Flow -9.61
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android